Regeneron Collaborates with Alnylam to Discover, Develop and Commercialize RNAi Therapeutics for Ophthalmic and CNS Disorders

Shots:

• Alnylam & Regeneron to co-discover RNAi therapies for eye and CNS diseases. Alnylam to receive $400M upfront, $400M equity at a price of $90/share, $200M as milestones and royalties on sales of products. Regeneron to get rights to develop & commercialize candidates for ocular diseases and to jointly lead CNS diseases program with an option to candidate selection with equal profit sharing
• The companies also target genes expressed in the liver including the evaluation of Regeneron’s P-I pozelimab (REGN3918) and Alnylam’s P-II cemdisiran. Regeneron to lead the combination’s development while Alnylam to take care of monothx with no changes in 2018 deal for NASH
• The companies collaborate for 5yrs involving 30 targets with an option to extend. Alnylam to receive $2.5M at the initiation of each program and $2.5M at the identification of lead candidates with $30M as annual discovery funding for each target

Click here to read full press release/ article | Ref: Alnylam | Image: Behance